

Based on the analysis of the "ZYDUSLIFE.NS" PDF report (generated 2026-01-10), here is my assessment from the perspective of a positional equity trader.

### ### Step 1: Audit the Data

#### \* **Data Present:**\*

- \* Multi-timeframe price charts (Daily, Weekly, 15-min).
- \* Key Moving Averages (EMA 20, 50, 200) and crossover status.
- \* Momentum Indicators (RSI, MACD with Histogram).
- \* Trend Indicators (Supertrend, Bollinger Bands).
- \* Relative Strength (RS) analysis against Benchmark (^CNXPHARMA).
- \* Volatility Analysis (Squeeze and ATR).
- \* Basic Fundamental Snapshot (Revenue, ROE, Valuation scores).

#### \* **Data Missing:**\*

\* **Volume Profile / Delivery %:** While daily volume bars are present, specific delivery data to confirm accumulation vs. intraday speculation is missing.

\* **Fibonacci Retracements:** No explicit retracement levels from the 2024 peak are drawn to identify major structural support.

\* **Confidence Level:** **High.** The technical data is robust and covers all necessary aspects (trend, momentum, volatility, and relative strength) to make an informed technical decision.

### ### Step 2: Analyze the Setup

\* **Price Structure & Trend:** The stock is in a **Strong Downtrend**. Price (894.90) is trading below the EMA 20 (917), EMA 50 (932), and EMA 200 (951). The alignment of EMAs (20 < 50 < 200) confirms a classic bearish "Death Cross" structure.

#### \* **Momentum & Volatility:**\*

\* **Volatility Squeeze:** Page 14 indicates a **Bearish Breakout** from a volatility squeeze on 2026-01-09. This is a highly negative signal, suggesting the expansion of volatility is occurring to the downside.

\* **Bollinger Bands:** The price is "walking the bands" downward and is currently below the Lower Band (898.11), indicating extreme weakness.

\* **RSI:** RSI is at 35.71. While approaching oversold territory, it has not yet formed a convincing bullish divergence that has been confirmed by price action.

\* **MACD:** There is a faint bullish divergence noted on Page 12, but the histogram is weak, and the signal has not translated into a price reversal.

\* **Relative Strength:** The stock has an RS Score of 45.7/100 and is labeled "Neutral" but lagging. It is underperforming the Pharma sector, which makes it a poor candidate for a long position in the current environment.

**Conclusion on Setup:** There is **no confluence** for a long entry at this moment. The stock is catching a falling knife. The bearish volatility breakout suggests the price could seek lower liquidity zones before stabilizing.

### ### Step 3: Formulate the Recommendation

**Recommendation:** **NO** (Do not enter at current market price).

**Rationale:** The stock has just triggered a fresh bearish volatility breakdown. Buying now fights the immediate momentum and three layers of overhead resistance (EMA 20, 50, and Supertrend).

#### **Conditional Plan (Watchlist for Reversal):**

Given the oversold nature (Price < Lower BB), a mean reversion trade is possible **if** momentum shifts. I would only consider a position if the stock reclaims immediate structural resistance.

- \* **Condition to Buy:** Price must close above the **Supertrend Resistance (936)** and the **EMA 50 (932)**. This invalidates the immediate downtrend and puts the price back into a neutral/bullish zone.
- \* **Entry Price:** **INR 938 - INR 940** (Wait for the daily close confirmation).
- \* **Stop Loss:** **INR 890** (Hard stop below the recent swing low/current price consolidation).
- \* **Take Profit:** **INR 1,040 - INR 1,050** (Targeting the previous breakdown level and EMA 200 overhead resistance).
- \* **Risk/Reward Ratio:** ~1:2.2 (Risking ~50 points to make ~110 points).
- \* **Upside Potential:** ~11.5% (Fits the 5-15% criteria).

## # News & Analyst Targets

Here is the latest research and information on **Zydus Lifesciences (ZYDUSLIFE)** for the week ending **January 10, 2026**.

### 1) Latest News for ZYDUSLIFE (Week of Jan 5 - Jan 10, 2026)

The most significant development this week is a major regulatory win in the domestic diabetes market.

- \* **CDSCO Panel Approval for Semaglutide (Jan 9, 2026):**
  - \* Zydus Lifesciences has received a key recommendation from the **Central Drugs Standard Control Organisation (CDSCO)** Subject Expert Committee (SEC).
  - \* The panel cleared the company to manufacture and market **Semaglutide Injection (15 mg/3 ml)**, a synthetic GLP-1 receptor agonist used for the treatment of **Type 2 Diabetes Mellitus**.
  - \* This approval follows the acceptance of Zydus's Phase III clinical trial report. Semaglutide is a high-demand drug class (similar to Ozempic/Wegovy) globally known for weight management and metabolic control benefits.
- \* **Upcoming FDA Catalyst (Scheduled for Jan 14, 2026):**
  - \* Investors are closely watching the upcoming **PDUFA (target action) date** of **January 14, 2026**, for **CUTX-101 (Copper Histidinate)**.
  - \* The US FDA is reviewing the New Drug Application (NDA) resubmitted by Zydus's subsidiary, Sentyln Therapeutics, for this treatment of Menkes disease. A decision is expected next week.

### 2) Brokerage Upgrades & Downgrades

Activity from brokerages has been mixed to neutral in recent months, with analysts focusing on the sustainability of US generics revenue.

- \* **MarketsMojo (Dec 2025):** Recently upgraded its technical evaluation of the stock to **"Mildly Bullish"** from a previous neutral/bearish stance, citing improved technical signals despite some pressure on operating margins.
- \* **Consensus View (Late 2025):** Most analysts have maintained a **HOLD** or **NEUTRAL** rating. The primary concern cited is valuation after the stock's significant run-up over the last two years and the high base of US sales (driven by products like Revlimid generics) which may normalize.

### 3) Other News Impacting ZYDUSLIFE

- \* **Recent US FDA Approvals (Q4 2025 Context):** The company continues to expand its US portfolio, which provides a floor for revenue expectations.
  - \* **Verapamil Hydrochloride ER Tablets:** Received final approval in late November 2025 (Cardiac treatment).
  - \* **Deflazacort Oral Suspension:** Approved in October 2025 (Treats Duchenne Muscular Dystrophy), adding a niche product to their US basket.
- \* **Biosimilar Expansion:** The approval of Semaglutide is part of a broader strategy to capture the Indian chronic therapy market, reducing dependence on the volatile US generics market.

### \*\*4) Latest Analyst Targets (2026 Outlook)\*\*

The consensus among the analyst community suggests limited immediate upside from current levels, with the stock trading near its fair value estimates.

Brokerage / Source	Rating / Stance	Target Price (INR)	Outlook / Notes
Alpha Spread Consensus	Buy/Hold	INR 1,035	Average 1-year forecast. Bull case sees INR 1,376.
MarketScreener Consensus	Hold	INR 1,014	Consensus average. Spread suggests tight valuation.
Simply Wall St	Neutral	INR 1,016	Based on statutory earnings forecasts for FY26/27.
Nomura	Neutral	INR 1,020	Maintained from previous update; wary of margin dip.
Motilal Oswal	Neutral	INR 1,210	Long-term constructive but valuations cap upside.

\*Note: Some specific brokerage targets are carried over from late 2025 reports as major updates are expected following the Q3 FY26 results usually released in February.\*


# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹894.90

Generated: 2026-01-10 10:19

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	45.7/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.960 [Neutral]</b>
3M RS:	<b>0.857 [Neutral]</b>
6M RS:	<b>0.900 [Neutral]</b>
1Y RS:	<b>0.954 [Neutral]</b>
:	

## == TURNAROUND ANALYSIS ==:


Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::


✓ Emerging RS:	1M (0.960) > 3M (0.857)
✓ Medium-term Lagging:	6M=0.900, 1Y=0.954 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline






## ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	917.46
EMA 50:	932.45
EMA 200:	951.28
Trend Status:	<b>Strong Downtrend</b>

ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	894.90
<b>Upper Band:</b>	933.47
<b>Middle Band (SMA 20):</b>	915.79
<b>Lower Band:</b>	898.11
<b>%B:</b>	-0.0908
<b>Band Width:</b>	0.0386
<b>Status:</b>	Below Lower Band
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2025-11-07 00:00:00+05:30</b>
<b>Recent Signal 2:</b>	<b>Buy Signal at 2025-12-18 00:00:00+05:30</b>


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	935.99
Signal Identified On:	2025-09-26

Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

MACD Line:	-5.71
Signal Line:	-5.92
Histogram:	0.21
Trend:	<b>Bullish</b>
Momentum:	<b>Weakening</b>
Signal:	None
Divergences Detected:	1
└ <b>Bullish Divergence:</b>	Date: 2026-01-09 00:00:00+05:30, Price: 894.90

ZYDUSLIFE.NS Price



ZYDUSLIFE.NS MACD (12, 26, 9)








# ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0386
ATR:	14.2571
Total Signals:	43
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30 (Pr




# ZYDUSLIFE.NS - Volatility Squeeze Analysis



## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	35.71
<b>Current Volume:</b>	797148
<b>Volume MA 20:</b>	482356
<b>Bullish Divergences:</b>	6
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
<b>Bullish Div 2:</b>	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

# ZYDUSLIFE.NS RSI-Volume Divergence Analysis




## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	958.59	894.9	2025-11-03
1 Day	DOWNTREND (Sell)	935.99	894.9	2025-09-26
15 Min	DOWNTREND (Sell)	903.86	893.6	2026-01-07

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Weakening	No Signal

ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)




ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)




ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - ZYDUSLIFE\_main



Trendlyne Snapshot - ZYDUSLIFE\_forecaster



Zydu  
s Lifesci  
ences - ZYDUSLIFE - stock price prediction, stock forecast, target price, analyst ratings from 29 analysts

Zydu  
s Lifesci  
ences has a share price target of Rs 1014, revenue growth forecast of 10.8%, and profit growth estimate of 2.8% for FY26, based on top 29 analyst calls.

Zydu  
s Lifesci  
ences FORECASTER - Analyst Estimates

FORECASTER DASHBOARD

